NFKB1 and COVID-19: The observed activation of NF‐κB in response to SARS‐CoV‐2 results in an escalated inflammatory response, a crucial factor in the virus's pathogenesis.[39] This activation highlights the NF‐κB pathway as a promising target for COVID‐19 treatment.[40] By employing the integrated cell line and drug target predictors within KGDRP, we could elucidate the drug mechanism within the BioHG.